Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
250.12B
Market cap250.12B
Price-Earnings ratio
27.01
Price-Earnings ratio27.01
Dividend yield
2.13%
Dividend yield2.13%
Average volume
2.70M
Average volume2.70M
High today
$474.40
High today$474.40
Low today
$460.00
Low today$460.00
Open price
$472.70
Open price$472.70
Volume
1.93M
Volume1.93M
52 Week high
$483.99
52 Week high$483.99
52 Week low
$312.39
52 Week low$312.39

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $464.15. The company's market cap stands at 250.12B, with a P/E ratio of 27.01 and a dividend yield of 2.13%.

On 2026-11-17, Amgen(AMGN) stock moved within a range of $460.00 to $474.40. With shares now at $464.15, the stock is trading +0.9% above its intraday low and -2.2% below the session's peak.

Trading activity shows a volume of 1.93M, compared to an average daily volume of 2.7M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $483.99 and a low of $312.39.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $483.99 and a low of $312.39.

AMGN News

Simply Wall St 10h
Amgen Could Be 42% Below Fair Value After Fresh Trial Results - Simply Wall St

...

Amgen Could Be 42% Below Fair Value After Fresh Trial Results - Simply Wall St
Investor's Business Daily 11h
Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness

Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data 11/11/2026 Amgen unveiled test results Wednesday that suggest it could have o...

Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness
TipRanks 19h
Amgen price target raised to $430 from $400 at Barclays

Barclays analyst Emily Field raised the firm’s price target on Amgen (AMGN) to $430 from $400 and keeps an Equal Weight rating on the shares post the Q3 report....

Analyst ratings

51%

of 35 ratings
Buy
31.4%
Hold
51.4%
Sell
17.1%

More AMGN News

Simply Wall St 2d
Read This Before Considering Amgen Inc. For Its Upcoming US$2.52 Dividend

It looks like Amgen Inc. ( ) is about to go ex-dividend in the next 4 days. The ex-dividend date occurs one day before the record date, which is the day on whic...

Read This Before Considering Amgen Inc. For Its Upcoming US$2.52 Dividend
Simply Wall St 2d
Phase 3 Sjögren’s Results Might Change The Case For Investing In Amgen

Amgen reported Phase 3 data in November 2026 showing clinically meaningful improvements with dazodalibep in Sjögren's disease and presented extensive new clinic...

Phase 3 Sjögren’s Results Might Change The Case For Investing In Amgen
The Motley Fool 3d
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Investors looking for stability in the healthcare sector often compare Amgen (AMGN -0.30%) and Vertex Pharmaceuticals (VRTX -0.74%). Choosing between these two...

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
TipRanks 5d
Balanced Outlook on Dazodalibep as Efficacy Strengths Face Safety and Dosing Uncertainties; Price Target Unchanged at $410

Amgen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on the st...

Simply Wall St 6d
What Does Amgen FDA Warning Mean For Investors?

Amgen (NasdaqGS:AMGN) received an FDA warning letter regarding a Vectibix promotional video that omitted key risk and indication details. The FDA letter cites...

What Does Amgen FDA Warning Mean For Investors?
Benzinga 6d
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears

Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients wit...

Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Seeking Alpha 6d
Amgen slips after late-stage trial data for Sjögren's disease therapy

Amgen (AMGN) shares fell in premarket trading on Wednesday after the California-based pharma giant announced detailed results from a late-stage trial for dazoda...

Amgen slips after late-stage trial data for Sjögren's disease therapy

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.